Tempus AI, Inc. (NASDAQ:TEM) shares are climbing today after the company unveiled a new AI-powered cancer diagnostic ...

Tempus HRD-RNA is an AI-driven, 1,660-gene logistic regression model designed to identify patients likely to respond to ...

Tempus AI Inc. TEM shares are up on Thursday as Mizuho initiated coverage on the health care-focused artificial intelligence ...

TEM rolls out new AI tools across oncology, cardiology and mental health, accelerating its push to reshape MedTech innovation.

Tempus AI TEM rose on Wednesday after the company unveiled its new HRD-RNA algorithm, an AI-driven tool designed to improve ...

CHICAGO--(BUSINESS WIRE)-- Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced a collaboration with Genialis, ...

Investing.com -- Tempus AI, Inc. (NASDAQ:TEM) stock rose 3.5% Wednesday after the precision medicine technology company announced the launch of its new HRD-RNA algorithm for cancer detection.

Tempus AI (TEM) stock jumps as Mizuho issues a new Outperform rating amd a $100 target on the company citing its growth prospects. Read more here.

At a virtual conference in November 2020, the winner of a biennial protein-structure-prediction challenge was announced: AlphaFold. Created by Google DeepMind, this computational tool had blown its ...

A machine learning algorithm used gene expression profiles of patients with gout to predict flares. The PyTorch neural network performed best, with an area under the curve of 65%. The PyTorch model ...